Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.63.

FOLD has been the topic of a number of analyst reports. Morgan Stanley dropped their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 16th. JPMorgan Chase & Co. lifted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $9.72 on Tuesday. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company’s 50-day moving average price is $10.80 and its two-hundred day moving average price is $10.59. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The stock has a market cap of $2.90 billion, a PE ratio of -28.59 and a beta of 0.68.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 30,401 shares of company stock valued at $352,038 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors have recently made changes to their positions in the company. OLD Second National Bank of Aurora acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. lifted its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $55,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.